NDAENTERALSUSPENSION
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
DUOPA (carbidopa and levodopa) by AbbVie is dopa decarboxylase inhibitors [moa]. Approved for parkinson disease. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUOPA is a combination of carbidopa and levodopa delivered as an enteral suspension for Parkinson's disease. It works by inhibiting DOPA decarboxylase, allowing levodopa to cross the blood-brain barrier and restore dopamine levels. This formulation addresses motor fluctuations in advanced Parkinson's patients who have inadequate response to oral medications.
$0.003BPart D
PeakDUOPA is at peak commercial maturity with 374 Part D claims in 2023; the team is likely stable in size with focus on maintaining market position against rising generic and branded alternatives.
Mechanism of Action
DOPA Decarboxylase Inhibitors
Pharmacologic Class:
Aromatic Amino Acid Decarboxylation Inhibitor
Indications (1)
Clinical Trials (2)
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
Started Jan 2016
213 enrolled
Advanced Parkinson's Disease
Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Started Mar 2009
52 enrolled
Parkinson Disease
Worked on DUOPA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.